InVivo Therapeutics Holdings Corp (NVIVQ)

[Pemmanuel]

I always expected the 6 months post the last patient. It is my belief that once submitted, the NSS will be rapidly approved. It is then up to the company to manage a smooth and efficient scale-up of production. And since that involves current management, I'll honestly say it is a cause for some concern, since they have shown themselves to be a bit amateurish. I do believe this becomes the standard of care for acute AIS-A thoracic. Hopefully migration to cervical looks promising in clinical, and can be abbreviated and added on in a quicker time frame.